The Latest Breaking News from Ginkgo Bioworks

The biotech industry is increasingly gaining prominence due to the growing prevalence of chronic disease and advancements in drug discovery and development. Given the industry’s solid growth prospects, it could be wise to buy quality biotech stocks, Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and United Therapeutics (UTHR). However, we think…

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company 

Cell programming platform operator Ginkgo Bioworks (DNA) went public late last year in an SPAC merger. Since then, the stock has plummeted more than 60% in price, closing yesterday’s session at $4.13. In addition, analysts have increased their loss per share expectations for the stock for this year. So, would…

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates.

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported 

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates. 

Ginkgo Bioworks Holdings Inc (NYSE: DNA) has 

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.